JUL 1 2 2004 E.

Sheet 1 of 2		(3)								
PTO/SB/08A		Party		ATTY DOCKET NO. SERIAL NO. 10/624,889						
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Angus George DALGLEISH et al.						
Date Submitt	ed: July	12, 2004	FILING DATE July 23, 2004			GROUP 1842/643				
ļ			U.	S. PATENT DOCUMENTS						
EXAMINER	T	DOCUMENT	DATE	NAME	CLASS		SUBCLASS	FILING DATE IF		
INITIAL	100	NUMBER	(M/D/Y)	DALGLEISH ET AL. 424			277.1	APPROPRIATE		
	A01	6,699,483	3/2/04	DALGLEISH ET AL.	AL. 424		211.1			
		• · · · · · · · · · · · · · · · · · · ·	FORE	IGN PATENT DOCUMEN	ITS					
		DOCUMENT	DATE	COUNTRY	CLAS	S	SUBCLASS	TRANSL		
	100	NUMBER WO93/06867	(M/D/Y)	WIPO				YES	NO	
ОН	A02	WO93/00007	4/93	WIFO						
DН	A03	WO97/24132	7/10/97	WIPO				_		
DH	A04	WO97/282255	8/7/97	WIPO						
J11		OTHER DOCU	MENT(S) (I	ncluding Author, Title, Dat	e, Pertine	nt Page	s, Etc.)	L		
DH	A05	ABLIN	J. Cance	r Res. Clin, Oncol. 123: 58	3-594 (19	97)				
DH	A06	BERTHON	Intl J Onc	cology, 6(2): 333-343 (199	5)			•		
DH	A07	BOON	Adv Can Res 58: 177-210 (1992)							
DH	A08	BRENNER ET AL.	Journal of Urology, pgs. 1575-1579 (1995) (abstract only)							
DH	A09	BRIGHT ET AL.	Cancer Research (57)(1): 995-1002 (1997)							
рН	A10	CURTI	Crit. Rev, in Oncology/Hematology 14:29-39 (1993)							
DH	A11	DERMER	Bio/Technology 12:320 (1994)							
DH	A12	DIEDERICHSEN et al.	Oncology Reports 5: 823-826 (1998)							
DH	A13	DILLMAN et al.	Cancer Biotherapy & Radiopharmaceuticals 15(2): 161-168 (2000)							
DH	A14	DREXLER ET AL.	Leukemia	a and Lymphoma 9:1-25 (1	1993)					
DH	A15	EMBLETON ET AL.	Immunol	Ser 23:181-207 (1984)						
DH	A16	ENGEL et al.	Scand. J. Immunol. 45: 463-470 (1997)							
DH	A17	ESPARAZA et al.		nology 131(5): 2117-2121						
DH	A18	FENTON et al.	J. of Imm	unotherapy 19(5): 364-37	4 1996)					
OH	A19	FOGEL et al.	J. Natl. Cancer Inst. 62(3):585-588 (1979)							
DH	A20	FRESHNEY	Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., New York, p4 (1983)							
DH	A21	GORELIK ET AL.	Journal of Supramolecular Structure 12: 385-402 (1979) (abstract only)							
DH	A22	GURA	Science	278:1041-1042 (1997)						
DH	A23	HARTWELL ET AL.	Science :	278:1064-1068 (1997)						
EXAMINER	Pr	-3/		DATE CON	SIDERED	2/	27/06			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DIPE 3025

Sheet 1 of 2 PTO/SB/08A									
PTO/SB/08A			<u> </u>	ATTY DOCKET NO	<u> </u>	SERIAL NO.			
1 10/05/041		PAPE	IRA	37945-0054	J .	10/624,889			
				0,040-0004		10/024,003			
INFORMA	TION D	ISCLOSURE STATE		APPLICANT					
IN OKWA		APPLICANT	-111-111	Angus George DA	ALGLEISH et a	1.			
	. 61	APPLICANT		Angus design basession of an					
				FILING DATE		GROUP			
Date Submitte	d: July	12, 2004		July 23, 2004		1842/643			
				ncluding Author, Title		nt Pages, Etc.)			
DH	A24	HROUDA et al.	BJU Inter	national 86: 742-748	(2000)				
ווע									
(0.1)	1) A25 HSU Tissue Culture Methods and Applications, Kruse and Patterson, Eds., Acad								
рН			NY, pgs. 764767 (1973)						
	A26	JÄGER et al.	Int. J. Cancer 71: 142-147 (1997)						
ŊН	~=~	UNOLIN CLUB.							
	A27	JAIN	Coi Am 271-59 C5 (1004)						
DH	A21	JAIN	Sci. Am. 271:58-65 (1994)						
וזע									
611	A28	KAYAGA et al.	Gene Therapy 6: 1475-1481 (1999)						
ĎН									
ŊН	A29	KUSUMOTO et al.	Cancer In	nmunol Immunother	50: 373-381 (20	001)			
ווע						·			
01]	A30	LEHNER et al.	Cancer In	nmunol Immunother	32: 173-178 (19	990)			
·DH			O 4.1001 11.		oz (,007			
	A31	MARBLE	Concorta	Jookhy Dlum m4/2) (44	007)				
$\mathcal{I}\mathcal{H}$	A31	MMADLE	Cancerv	eekly Plus, p4(2) (19	997)				
21.									
ΔL	A32	MORAN	American	Medical News 42, 3	9, 23 (1999)				
DH									
(1)	A33	SCHREIBER et al.	Human G	ene Therapy 10: 983	3-993 (1999)				
DH									
	A34	TAMURA et al.	Science 2	78: 117-120 (1997)					
DH	1,04	174morovecan	00101100 2	10. 117-120 (1337)					
	A25	TOISOTETAL	01:-110	D ((0), 000	0.44.(4000)				
ОH	A35	TRIEST ET AL.	Clinical C	ancer Res. 4(8): 200	9-14 (1998)				
DH	A36	VERMORKEN et	The Lanc	et 353: 345-350 (199	99)				
<i>ח</i>		al.							
017	A37	VIEWEG ET AL.	Cancer R	esearch 54: 1760-17	'65 (1994)				
DH					• •				
0.17	A38	VOLPE	Cancer G	enet Cytogenet 34: 1	125-134 (1988)	· · · · · · · · · · · · · · · · · · ·			
DH	7.00	102,2	Ouriou, O	chot Oylogonot 04.	120-104 (1000)				
017	A20	MULCEAL	Jati Lasa	77(C), 007 O4 (4)	2001				
9H	A39	WU ET AL.	inti J cand	er, 77(6): 887-94 (19	998)				
<i>J</i> ,,,									
						\			
		1				•			
					-				
EXAMINER	1	2/		DATE	CONSIDERED	2/27/06			
	1/2	_//			· · ·	2/27/06			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NOV 2 2 2004 2

Chast 1 of 1		-1 ~	<u>\$</u>							
Sheet 1 of 1 PTO/SB/08A RADEWARE RADEWARE			ATTY DOCKET NO. 37945-0054							
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Angus George DALGLEISH et al.						
Date Submitte	ed: Nov	vember 22, 2004		FILING DATE GROUP 1642 1643						
			U.	S. PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE (M/D/Y)	NAME	NAME CLASS		FILING DATE IF APPROPRIATE			
	<u> </u>		 		 					
		<u> </u>	-		-					
					-	-				
			SOPI	TO CATELY DOCUMEN						
	т	TOOCHMENT		EIGN PATENT DOCUMEN		T CURCUACE	TRANSI ATION			
	 	DOCUMENT NUMBER	DATE (M/D/Y)	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO			
	 									
			<u> </u>							
		OTUER DOCL	11 4TAIT(S) (I	Author Title Date	- Cartingat Pr	540				
nu	B01	MAITLAND et al.	MENI (O) (III	ncluding Author, Title, Date Research 155: 133-142 (2	<u>3, Penineni ra</u> 2004)	ages, Etc.)				
DH	BU I	MAH DAND Et al.	Kaulation	Research 150, 100-172 (a	.001)					
	<u> </u>		 							
			 							
	 		 							
										
		· .								
		ļ	 			·				
			-							
EXAMINER	2	2/2	1	DATE CONS	DATE CONSIDERED 2/27/06					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.